Phase 4 Trial of Viloxazine ER Shows Real-World Gains for ADHD With Comorbid Depression, Anxiety
Psychiatric Times
A phase 4 trial demonstrated that extended-release viloxazine effectively improves symptoms of attention-deficit/hyperactivity disorder in real-world clinical settings. This benefit was specifically observed in patients who also have comorbid depression and anxiety.
All articles from 13 August 2026. Summaries are AI-generated and may contain errors; the linked article is the authority.